PTAB proceedings are a vital tool in the biologics space, despite low usage rates
While generic enthusiasm for IPRs has waned, administrative challenges are of growing importance to biosimilar producers
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.